Chih Hui Lin

Chief Executive Officer bei SYNMOSA BIOPHARMA CORPORATION

Health Technology

Consumer Services

Profil

Chih Hui Lin is currently the Chairman, President & General Manager at Synmosa Biopharma Corp.
He is also the Chairman at Yu Chiao Co. Ltd., InnoPharmax, Inc., U-Liang Pharmaceutical Co. Ltd., and Intech Biopharm Ltd.
Mr. Lin completed his undergraduate degree at Taipei Medical University.

Aktive Positionen von Chih Hui Lin

Unternehmen	Position	Beginn
SYNMOSA BIOPHARMA CORPORATION	Chief Executive Officer	25.02.2011
INNOPHARMAX INC.	Chairman	21.03.2008
INTECH BIOPHARM CORPORATION	Chairman	28.10.2010
Yu Chiao Co. Ltd.	Chairman	-
U-Liang Pharmaceutical Co. Ltd. U-Liang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Synmosa Biopharma Corp., U-Liang Pharmaceutical Co. Ltd. is a Taiwanese company that manufactures and distributes pharmaceutical products. The private company is based in Taoyuan, Taiwan. U-Liang Pharmaceutical Co. was acquired by Synmosa Biopharma Corp. on March 07, 2013 for $2.50 million.	Chairman	-

Alle aktiven Positionen von Chih Hui Lin

Ausbildung von Chih Hui Lin

Taipei Medical University

Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Chih Hui Lin im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	3
SYNMOSA BIOPHARMA CORPORATION	Health Technology
INNOPHARMAX INC.	Health Technology
INTECH BIOPHARM CORPORATION	Health Technology

Private Unternehmen	2
Yu Chiao Co. Ltd.
U-Liang Pharmaceutical Co. Ltd. U-Liang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Synmosa Biopharma Corp., U-Liang Pharmaceutical Co. Ltd. is a Taiwanese company that manufactures and distributes pharmaceutical products. The private company is based in Taoyuan, Taiwan. U-Liang Pharmaceutical Co. was acquired by Synmosa Biopharma Corp. on March 07, 2013 for $2.50 million.	Health Technology